Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.
Identifieur interne : 001F80 ( PubMed/Corpus ); précédent : 001F79; suivant : 001F81Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.
Auteurs : Christopher Mcguigan ; Alshaimaa Hassan-Abdallah ; Sheila Srinivasan ; Yikang Wang ; Adam Siddiqui ; Susan M. Daluge ; Kristjan S. Gudmundsson ; Huiqiang Zhou ; Ed W. Mclean ; Jennifer P. Peckham ; Thimysta C. Burnette ; Harry Marr ; Richard Hazen ; Lynn D. Condreay ; Lance Johnson ; Jan BalzariniSource :
- Journal of medicinal chemistry [ 0022-2623 ] ; 2006.
English descriptors
- KwdEn :
- Adenosine (analogs & derivatives), Adenosine (chemical synthesis), Adenosine (pharmacology), Animals, Anti-HIV Agents (chemical synthesis), Anti-HIV Agents (pharmacology), Antiviral Agents (chemical synthesis), Antiviral Agents (pharmacology), Cell Line, HIV-1 (drug effects), HIV-2 (drug effects), Hepatitis B virus (drug effects), Humans, In Vitro Techniques, Intestinal Mucosa (metabolism), Liver (metabolism), Nucleotides (chemical synthesis), Nucleotides (pharmacology), Organophosphorus Compounds (chemical synthesis), Organophosphorus Compounds (pharmacology), Structure-Activity Relationship.
- MESH :
- chemical , analogs & derivatives : Adenosine.
- chemical , chemical synthesis : Adenosine, Anti-HIV Agents, Antiviral Agents, Nucleotides, Organophosphorus Compounds.
- chemical , pharmacology : Adenosine, Anti-HIV Agents, Antiviral Agents, Nucleotides, Organophosphorus Compounds.
- drug effects : HIV-1, HIV-2, Hepatitis B virus.
- metabolism : Intestinal Mucosa, Liver.
- Animals, Cell Line, Humans, In Vitro Techniques, Structure-Activity Relationship.
Abstract
We report the application of phosphoramidate pronucleotide (ProTide) technology to the antiviral agent carbocyclic L-d4A (L-Cd4A). The phenyl methyl alaninyl parent ProTide of L-Cd4A was prepared by Grignard-mediated phosphorochloridate reaction and resulted in a compound with significantly improved anti-HIV (2600-fold) and HBV activity. We describe modifications of the aryl, ester, and amino acid regions of the ProTide and how these changes affect antiviral activity and metabolic stability. Separate and distinct SARs were noted for HIV and HBV. Additionally, ProTides were prepared from the D-nucleoside D-Cd4A and the dideoxy analogues L-CddA and D-CddA. These compounds showed more modest potency improvements over the parent drug. In conclusion, the ProTide approach is highly successful when applied to L-Cd4A with potency improvements in vitro as high as 9000-fold against HIV. With a view to preclinical candidate selection we carried out metabolic stability studies using cynomolgus monkey liver and intestinal S9 fractions.
DOI: 10.1021/jm060776w
PubMed: 17125274
Links to Exploration step
pubmed:17125274Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.</title><author><name sortKey="Mcguigan, Christopher" sort="Mcguigan, Christopher" uniqKey="Mcguigan C" first="Christopher" last="Mcguigan">Christopher Mcguigan</name><affiliation><nlm:affiliation>Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK. mcguigan@cardiff.ac.uk</nlm:affiliation></affiliation></author><author><name sortKey="Hassan Abdallah, Alshaimaa" sort="Hassan Abdallah, Alshaimaa" uniqKey="Hassan Abdallah A" first="Alshaimaa" last="Hassan-Abdallah">Alshaimaa Hassan-Abdallah</name></author><author><name sortKey="Srinivasan, Sheila" sort="Srinivasan, Sheila" uniqKey="Srinivasan S" first="Sheila" last="Srinivasan">Sheila Srinivasan</name></author><author><name sortKey="Wang, Yikang" sort="Wang, Yikang" uniqKey="Wang Y" first="Yikang" last="Wang">Yikang Wang</name></author><author><name sortKey="Siddiqui, Adam" sort="Siddiqui, Adam" uniqKey="Siddiqui A" first="Adam" last="Siddiqui">Adam Siddiqui</name></author><author><name sortKey="Daluge, Susan M" sort="Daluge, Susan M" uniqKey="Daluge S" first="Susan M" last="Daluge">Susan M. Daluge</name></author><author><name sortKey="Gudmundsson, Kristjan S" sort="Gudmundsson, Kristjan S" uniqKey="Gudmundsson K" first="Kristjan S" last="Gudmundsson">Kristjan S. Gudmundsson</name></author><author><name sortKey="Zhou, Huiqiang" sort="Zhou, Huiqiang" uniqKey="Zhou H" first="Huiqiang" last="Zhou">Huiqiang Zhou</name></author><author><name sortKey="Mclean, Ed W" sort="Mclean, Ed W" uniqKey="Mclean E" first="Ed W" last="Mclean">Ed W. Mclean</name></author><author><name sortKey="Peckham, Jennifer P" sort="Peckham, Jennifer P" uniqKey="Peckham J" first="Jennifer P" last="Peckham">Jennifer P. Peckham</name></author><author><name sortKey="Burnette, Thimysta C" sort="Burnette, Thimysta C" uniqKey="Burnette T" first="Thimysta C" last="Burnette">Thimysta C. Burnette</name></author><author><name sortKey="Marr, Harry" sort="Marr, Harry" uniqKey="Marr H" first="Harry" last="Marr">Harry Marr</name></author><author><name sortKey="Hazen, Richard" sort="Hazen, Richard" uniqKey="Hazen R" first="Richard" last="Hazen">Richard Hazen</name></author><author><name sortKey="Condreay, Lynn D" sort="Condreay, Lynn D" uniqKey="Condreay L" first="Lynn D" last="Condreay">Lynn D. Condreay</name></author><author><name sortKey="Johnson, Lance" sort="Johnson, Lance" uniqKey="Johnson L" first="Lance" last="Johnson">Lance Johnson</name></author><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17125274</idno><idno type="pmid">17125274</idno><idno type="doi">10.1021/jm060776w</idno><idno type="wicri:Area/PubMed/Corpus">001F80</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.</title><author><name sortKey="Mcguigan, Christopher" sort="Mcguigan, Christopher" uniqKey="Mcguigan C" first="Christopher" last="Mcguigan">Christopher Mcguigan</name><affiliation><nlm:affiliation>Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK. mcguigan@cardiff.ac.uk</nlm:affiliation></affiliation></author><author><name sortKey="Hassan Abdallah, Alshaimaa" sort="Hassan Abdallah, Alshaimaa" uniqKey="Hassan Abdallah A" first="Alshaimaa" last="Hassan-Abdallah">Alshaimaa Hassan-Abdallah</name></author><author><name sortKey="Srinivasan, Sheila" sort="Srinivasan, Sheila" uniqKey="Srinivasan S" first="Sheila" last="Srinivasan">Sheila Srinivasan</name></author><author><name sortKey="Wang, Yikang" sort="Wang, Yikang" uniqKey="Wang Y" first="Yikang" last="Wang">Yikang Wang</name></author><author><name sortKey="Siddiqui, Adam" sort="Siddiqui, Adam" uniqKey="Siddiqui A" first="Adam" last="Siddiqui">Adam Siddiqui</name></author><author><name sortKey="Daluge, Susan M" sort="Daluge, Susan M" uniqKey="Daluge S" first="Susan M" last="Daluge">Susan M. Daluge</name></author><author><name sortKey="Gudmundsson, Kristjan S" sort="Gudmundsson, Kristjan S" uniqKey="Gudmundsson K" first="Kristjan S" last="Gudmundsson">Kristjan S. Gudmundsson</name></author><author><name sortKey="Zhou, Huiqiang" sort="Zhou, Huiqiang" uniqKey="Zhou H" first="Huiqiang" last="Zhou">Huiqiang Zhou</name></author><author><name sortKey="Mclean, Ed W" sort="Mclean, Ed W" uniqKey="Mclean E" first="Ed W" last="Mclean">Ed W. Mclean</name></author><author><name sortKey="Peckham, Jennifer P" sort="Peckham, Jennifer P" uniqKey="Peckham J" first="Jennifer P" last="Peckham">Jennifer P. Peckham</name></author><author><name sortKey="Burnette, Thimysta C" sort="Burnette, Thimysta C" uniqKey="Burnette T" first="Thimysta C" last="Burnette">Thimysta C. Burnette</name></author><author><name sortKey="Marr, Harry" sort="Marr, Harry" uniqKey="Marr H" first="Harry" last="Marr">Harry Marr</name></author><author><name sortKey="Hazen, Richard" sort="Hazen, Richard" uniqKey="Hazen R" first="Richard" last="Hazen">Richard Hazen</name></author><author><name sortKey="Condreay, Lynn D" sort="Condreay, Lynn D" uniqKey="Condreay L" first="Lynn D" last="Condreay">Lynn D. Condreay</name></author><author><name sortKey="Johnson, Lance" sort="Johnson, Lance" uniqKey="Johnson L" first="Lance" last="Johnson">Lance Johnson</name></author><author><name sortKey="Balzarini, Jan" sort="Balzarini, Jan" uniqKey="Balzarini J" first="Jan" last="Balzarini">Jan Balzarini</name></author></analytic><series><title level="j">Journal of medicinal chemistry</title><idno type="ISSN">0022-2623</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (analogs & derivatives)</term><term>Adenosine (chemical synthesis)</term><term>Adenosine (pharmacology)</term><term>Animals</term><term>Anti-HIV Agents (chemical synthesis)</term><term>Anti-HIV Agents (pharmacology)</term><term>Antiviral Agents (chemical synthesis)</term><term>Antiviral Agents (pharmacology)</term><term>Cell Line</term><term>HIV-1 (drug effects)</term><term>HIV-2 (drug effects)</term><term>Hepatitis B virus (drug effects)</term><term>Humans</term><term>In Vitro Techniques</term><term>Intestinal Mucosa (metabolism)</term><term>Liver (metabolism)</term><term>Nucleotides (chemical synthesis)</term><term>Nucleotides (pharmacology)</term><term>Organophosphorus Compounds (chemical synthesis)</term><term>Organophosphorus Compounds (pharmacology)</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Adenosine</term><term>Anti-HIV Agents</term><term>Antiviral Agents</term><term>Nucleotides</term><term>Organophosphorus Compounds</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adenosine</term><term>Anti-HIV Agents</term><term>Antiviral Agents</term><term>Nucleotides</term><term>Organophosphorus Compounds</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>HIV-2</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Intestinal Mucosa</term><term>Liver</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Humans</term><term>In Vitro Techniques</term><term>Structure-Activity Relationship</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report the application of phosphoramidate pronucleotide (ProTide) technology to the antiviral agent carbocyclic L-d4A (L-Cd4A). The phenyl methyl alaninyl parent ProTide of L-Cd4A was prepared by Grignard-mediated phosphorochloridate reaction and resulted in a compound with significantly improved anti-HIV (2600-fold) and HBV activity. We describe modifications of the aryl, ester, and amino acid regions of the ProTide and how these changes affect antiviral activity and metabolic stability. Separate and distinct SARs were noted for HIV and HBV. Additionally, ProTides were prepared from the D-nucleoside D-Cd4A and the dideoxy analogues L-CddA and D-CddA. These compounds showed more modest potency improvements over the parent drug. In conclusion, the ProTide approach is highly successful when applied to L-Cd4A with potency improvements in vitro as high as 9000-fold against HIV. With a view to preclinical candidate selection we carried out metabolic stability studies using cynomolgus monkey liver and intestinal S9 fractions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17125274</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2623</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>24</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J. Med. Chem.</ISOAbbreviation></Journal><ArticleTitle>Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.</ArticleTitle><Pagination><MedlinePgn>7215-26</MedlinePgn></Pagination><Abstract><AbstractText>We report the application of phosphoramidate pronucleotide (ProTide) technology to the antiviral agent carbocyclic L-d4A (L-Cd4A). The phenyl methyl alaninyl parent ProTide of L-Cd4A was prepared by Grignard-mediated phosphorochloridate reaction and resulted in a compound with significantly improved anti-HIV (2600-fold) and HBV activity. We describe modifications of the aryl, ester, and amino acid regions of the ProTide and how these changes affect antiviral activity and metabolic stability. Separate and distinct SARs were noted for HIV and HBV. Additionally, ProTides were prepared from the D-nucleoside D-Cd4A and the dideoxy analogues L-CddA and D-CddA. These compounds showed more modest potency improvements over the parent drug. In conclusion, the ProTide approach is highly successful when applied to L-Cd4A with potency improvements in vitro as high as 9000-fold against HIV. With a view to preclinical candidate selection we carried out metabolic stability studies using cynomolgus monkey liver and intestinal S9 fractions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGuigan</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK. mcguigan@cardiff.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan-Abdallah</LastName><ForeName>Alshaimaa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Sheila</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yikang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Daluge</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Gudmundsson</LastName><ForeName>Kristjan S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Huiqiang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Ed W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Peckham</LastName><ForeName>Jennifer P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Burnette</LastName><ForeName>Thimysta C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Marr</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hazen</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Condreay</LastName><ForeName>Lynn D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Lance</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Balzarini</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015498" MajorTopicYN="N">HIV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009943" MajorTopicYN="N">Organophosphorus Compounds</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17125274</ArticleId><ArticleId IdType="doi">10.1021/jm060776w</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001F80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17125274
|texte= Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17125274" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |